Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gen-Probe Adds European Reach Through $132 Million Tepnel Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Gen-Probe will double its European sales force and expand its existing molecular diagnostics portfolio through the $132.2 million purchase of UK-based Tepnel Life Sciences

You may also be interested in...



Gen-Probe Adds Influenza Tests To Diagnostics Portfolio With Prodesse Buy

Nucleic acid test maker Gen-Probe will gain a growing pipeline of molecular diagnostics for infectious diseases and add flu tests for the first time through its purchase of privately-held Prodesse, announced Oct. 6

Gen-Probe Adds Influenza Tests To Diagnostics Portfolio With Prodesse Buy

Nucleic acid test maker Gen-Probe will gain a growing pipeline of molecular diagnostics for infectious diseases and add flu tests for the first time through its purchase of privately-held Prodesse, announced Oct. 6

Innogenetics Weighs Solvay’s Sweetened Takeover Offer Trumping Gen-Probe

Gen-Probe says it will not increase its offer for Belgian molecular diagnostics firm Innogenetics now that drug maker Solvay has submitted a higher bid, worth $316 million for all of Innogenetics' outstanding shares

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel